Your browser doesn't support javascript.
Anti-SARS-CoV-2 seroprevalence in King County, WA-Cross-sectional survey, August 2020.
Cowgill, Karen D; Erosheva, Elena A; Elder, Adam; Miljacic, Ljubomir; Buskin, Susan; Duchin, Jeffrey S.
  • Cowgill KD; Department of Global Health, School of Public Health, University of Washington, Seattle, Washington, United States of America.
  • Erosheva EA; Department of Statistics, School of Social Work, and the Center for Statistics and the Social Sciences, University of Washington, Seattle, Washington, United States of America.
  • Elder A; Department of Biostatistics, School of Public Health, University of Washington, Seattle, Washington, United States of America.
  • Miljacic L; The Mountain-Whisper-Light, Seattle, Washington, United States of America.
  • Buskin S; Public Health-Seattle & King County, Seattle, Washington, United States of America.
  • Duchin JS; Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, United States of America.
PLoS One ; 17(8): e0272783, 2022.
Article in English | MEDLINE | ID: covidwho-2002309
ABSTRACT
We conducted a seroprevalence survey to estimate the true number of infections with SARS-CoV-2, the virus that causes COVID-19, in King County as of August 2020 by measuring the proportion of residents from who had antibodies against the virus. Participants from 727 households took part in a cross-sectional address-based household survey with random and non-random samples and provided dried blood spots that were tested for total antibody against the viral nucleocapsid protein, with confirmatory testing for immunoglobulin G against the spike protein. The data were weighted to match King County's population based on sex, age group, income, race, and Hispanic status. After weighting and accounting for the accuracy of the tests, our best overall estimate of anti-SARS-CoV-2 seroprevalence in King County as of August 2020 is 3.9% (95% confidence interval (CI) 2.4%-6.0%) with an effective sample size of 589. Comparing seroprevalence with positive test reports, our survey suggests that viral testing underestimated incidence by a factor of about five and suggests that the proportion of cases that were serious (based on hospitalization) or fatal was 2.4% and 0.8%, respectively. Prevalence varied by subgroup; households reporting incomes at or below $100,000 in 2019 had nearly five times higher estimated antibody prevalence than those with incomes above $100,000. Those reporting non-White/non-Asian race had roughly seven times higher estimated antibody prevalence than those reporting White race. This survey was noteworthy for including people of all ages; among all age groups, the weighted estimate of prevalence was highest in older teens and young adults and lowest in young children, although these differences were not statistically significant.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Randomized controlled trials Limits: Adolescent / Adult / Child / Child, preschool / Humans / Young adult Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0272783

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Randomized controlled trials Limits: Adolescent / Adult / Child / Child, preschool / Humans / Young adult Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0272783